Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
about
Lessons from the past and charting the future of marine natural products drug discovery and chemical biologyHomopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome bindingTrial Watch: Proteasomal inhibitors for anticancer therapyAntileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).The resistance mechanisms of proteasome inhibitor bortezomib.Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.Multicolor monitoring of the proteasome's catalytic signature.The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.From bortezomib to other inhibitors of the proteasome and beyond.Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells.The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapyInhibition of the human proteasome by imidazoline scaffolds.Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolismPiperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells.Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.Proteasome inhibitors in acute leukemia.Harnessing proteasome dynamics and allostery in drug design.Proteasome inhibitors as experimental therapeutics of autoimmune diseases.Construction of a recombinant lentivirus-mediated shRNA expression vector targeting the human PSMD10 gene and validation of RNAi efficiency in RPMI‑8226 multiple myeloma cells.NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.Alantolactone induces G1 phase arrest and apoptosis of multiple myeloma cells and overcomes bortezomib resistance.Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells.Molecular mechanisms of acquired proteasome inhibitor resistance.Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity.Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells.Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.(Immuno)proteasomes as therapeutic target in acute leukemia.Histone deacetylase inhibitor NaBut suppresses cell proliferation and induces apoptosis by targeting p21 in multiple myeloma.Positioning of proteasome inhibitors in therapy of solid malignancies.CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.
P2860
Q26863108-6380397B-4F66-449B-8D87-85719D1CF68BQ27677425-0878C22C-A7F1-4A94-B077-0495FCBA5983Q28082910-C818CDDA-75A1-4F79-869E-EDCB330BD716Q33742779-738E34E7-273D-432A-94C1-205900755D2CQ34256126-38116E9B-B5E8-4FB2-B3F7-72FA2A5E6E9EQ35024457-A310BD47-560E-4784-BA41-B6546155847BQ35121111-C3B59B86-E8F5-4635-A635-0FFA338103A8Q36115692-0B0530D0-9ABB-48E3-97FA-C8A67330B27EQ36141927-F01C3352-FF17-4C4D-ABEC-D9F59DB0F055Q36691554-4061ACC6-B0D9-4734-A9B5-FC813B29DB2BQ36852277-CDF3CE38-9C7A-4528-96D1-08625E0F275EQ37015742-D9C16C7B-2100-46DF-B0A5-68EAFEA2C57AQ37132187-59C1734E-A67E-4814-BE28-6DBBBBBB9BDCQ37233146-6ECE96FE-D506-4053-B6B3-A15109A7CC8AQ37351110-841FB346-ED07-40C3-AAAE-5FD036C8B7AEQ37377911-8C515E8C-D10F-469F-80D3-FE3708DFD858Q37396016-2157EEE2-75AC-4B5A-97D9-C9E0DEADCC67Q37687419-01CE43C6-1EDC-4385-8B01-409BDBF1DDDBQ37688848-0BBDA9EB-A018-4B37-9B44-52259226706FQ38019864-1225CCC7-85F9-4654-B3F0-71924A702FBAQ38088003-F5265C18-9CE6-4F9E-B648-20439DD5E6D7Q38177328-86F70932-A2F8-4653-8E94-6CC6D4EB7A43Q38427697-3ED7FB95-1E39-447D-BCBE-485084ABACA9Q38698061-0DA77B87-AB71-47A2-93D3-6FA9B96C005EQ38855262-CB9C569A-3842-4A2E-B04D-3C37CEAAA2A3Q38868587-33BC38CD-65DD-48BC-9200-ADF8C8DE6634Q39034873-23517DB2-54E9-4EA0-87D1-8006FC5F0499Q39184945-C84C3FD2-BCE6-4129-840D-BF9C0FB42DCBQ39278628-7074E70A-FCBE-491F-BAB6-9A1357CD7A49Q40139788-264AB416-2898-401C-9A88-FDABDB60099FQ41056091-EBBE7383-DB4D-4872-9BB1-9193F3682B47Q41543982-5217C6F0-BD12-42C2-828B-B8A04A28279AQ41554672-B3CF23DF-2DD0-4C3E-A275-F73769CCC482Q41607725-82A554A5-CFF2-4FBB-973A-7D677FBF8564Q42762683-6494D0B1-6E36-45E5-A32F-166807F24C6DQ43097558-D1DFF135-1D09-45F0-879C-3D5D6E7D8645Q47131929-4348351E-167E-4179-8B96-EA6C452A872EQ47175684-4F1AA1BA-41FC-41A0-A07A-1E319AE9D267Q47353792-1667541D-0572-4499-BEA3-012179DEEC26Q49660927-8DD39512-C18F-41B0-A700-E3C93633FD82
P2860
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Impaired bortezomib binding to ...... resistance in leukemia cells.
@en
Impaired bortezomib binding to ...... resistance in leukemia cells.
@nl
type
label
Impaired bortezomib binding to ...... resistance in leukemia cells.
@en
Impaired bortezomib binding to ...... resistance in leukemia cells.
@nl
prefLabel
Impaired bortezomib binding to ...... resistance in leukemia cells.
@en
Impaired bortezomib binding to ...... resistance in leukemia cells.
@nl
P2093
P2860
P356
P1433
P1476
Impaired bortezomib binding to ...... b resistance in leukemia cells
@en
P2093
C H van Zantwijk
D Niewerth
G J L Kaspers
J van Meerloo
K Vojtekova
N E Franke
P2860
P2888
P304
P356
10.1038/LEU.2011.256
P577
2011-09-23T00:00:00Z